Dr. Jeffrey Flier, a diabetes and obesity researcher at Harvard, said the results were promising, adding that MariTide could be a future player in a highly competitive market. He emphasized that the initial findings suggest MariTide may offer significant weight loss benefits and could address the growing obesity epidemic, particularly with its less frequent dosing schedule compared to existing treatments. This could enhance patient adherence and overall treatment outcomes in the long run.
Dr. Jay Bradner, the company's chief scientific officer, noted a surprising effect of the drug: When the trial ended, many participants maintained their weight loss for as long as 150 days. This points to the potential of MariTide to deliver sustained weight management results, possibly reducing the need for daily or weekly doses. This not only makes it attractive for patients but also suggests innovative treatment regimens that could emerge from its use.
Collection
[
|
...
]